Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)UnknownNCT05142865
What this trial is testing

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Who this might be right for
Advanced or Metastatic EP-NEC
Huazhong University of Science and Technology 30
Testing effectiveness (Phase 2)Looking for participantsNCT07518602
What this trial is testing

Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

Who this might be right for
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Sun Yat-sen University 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07510594
What this trial is testing

A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC

Who this might be right for
Large-Cell Neuroendocrine Carcinoma of the LungExtrapulmonary Neuroendocrine Carcinoma
Tianjin Medical University Cancer Institute and Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT06503146
What this trial is testing

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Who this might be right for
SarcomaSmall Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)Mesothelioma+7 more
National Cancer Institute (NCI) 320
Testing effectiveness (Phase 2)Looking for participantsNCT07278479
What this trial is testing

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Who this might be right for
Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)+4 more
Molecular Partners AG 138
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Early research (Phase 1)Not Yet RecruitingNCT07488923
What this trial is testing

A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)

Who this might be right for
Small Cell Lung Cancer (SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)+1 more
Moonlight Bio, Inc 110